Portal de Periódicos da CAPES

Are differentially expressed micro RNA s useful in the diagnostics of malignant pleural mesothelioma?

2012; Wiley; Volume: 120; Issue: 9 Linguagem: Inglês

10.1111/j.1600-0463.2012.02891.x

1600-0463

Morten Andersen, Morten Grauslund, Marwa Muhammad‐Ali, Jesper Ravn, Jens Benn Sørensen, Claus B. Andersen, Eric Santoni‐Rugiu,

Tissue Engineering and Regenerative Medicine

APMISVolume 120, Issue 9 p. 767-769 Letter to the Editor Are differentially expressed microRNAs useful in the diagnostics of malignant pleural mesothelioma? Morten Andersen, Corresponding Author Morten Andersen Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkE-mail: [email protected]Search for more papers by this authorMorten Grauslund, Morten Grauslund Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkSearch for more papers by this authorMarwa Muhammad-Ali, Marwa Muhammad-Ali Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkSearch for more papers by this authorJesper Ravn, Jesper Ravn Department of Thoracic Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkSearch for more papers by this authorJens Benn Sørensen, Jens Benn Sørensen Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkSearch for more papers by this authorClaus B. Andersen, Claus B. Andersen Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkSearch for more papers by this authorEric Santoni-Rugiu, Eric Santoni-Rugiu Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkSearch for more papers by this author Morten Andersen, Corresponding Author Morten Andersen Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkE-mail: [email protected]Search for more papers by this authorMorten Grauslund, Morten Grauslund Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkSearch for more papers by this authorMarwa Muhammad-Ali, Marwa Muhammad-Ali Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkSearch for more papers by this authorJesper Ravn, Jesper Ravn Department of Thoracic Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkSearch for more papers by this authorJens Benn Sørensen, Jens Benn Sørensen Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkSearch for more papers by this authorClaus B. Andersen, Claus B. Andersen Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkSearch for more papers by this authorEric Santoni-Rugiu, Eric Santoni-Rugiu Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkSearch for more papers by this author First published: 05 March 2012 https://doi.org/10.1111/j.1600-0463.2012.02891.xCitations: 8Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317–31. 2Shi M, Fraire AE, Chu P, Cornejo K, Woda BA, Dresser KA, et al. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol 2011; 35: 878–82. 3Zimling ZG, Jørgensen A, Santoni-Rugiu E. The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas. Histopathology 2012; 60: e96–105. 4Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev 2011; 91: 827–87. 5Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257–61. 6Siebolts U, Varnholt H, Drebber U, Dienes HP, Wickenhauser C, Odenthal M. Tissues from routine pathology archives are suitable for micro-RNA analyses by quantitative PCR. J Clin Pathol 2009; 62: 84–8. 7Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D, et al. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One 2011; 6: e18232. 8Balatti V, Maniero S, Ferracin M, Veronese A, Negrini M, Ferrocci G, et al. MicroRNAs dysregulation in human malignant pleural mesothelioma. J Thorac Oncol 2011; 6: 844–51. 9Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, et al. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn 2010; 12: 771–9. 10Gee GV, Koestler DC, Christensen BC, Sugarbaker DJ, Ugolini D, Ivaldi GP, et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer 2010; 127: 2859–69. 11Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 2010; 42: 312–9. 12Mineo TC, Ambrogi V, Cufari ME, Pompeo E. May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma? Eur J Cardiothorac Surg 2010; 38: 245–52. 13Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008; 33: 502–6. Citing Literature Volume120, Issue9September 2012Pages 767-769 ReferencesRelatedInformation